CA1329541C - Pharmaceutical composition for relieving side effects of platinum-containing drugs - Google Patents

Pharmaceutical composition for relieving side effects of platinum-containing drugs

Info

Publication number
CA1329541C
CA1329541C CA000590264A CA590264A CA1329541C CA 1329541 C CA1329541 C CA 1329541C CA 000590264 A CA000590264 A CA 000590264A CA 590264 A CA590264 A CA 590264A CA 1329541 C CA1329541 C CA 1329541C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
ulinastatin
cisplatinum
platinum
side effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000590264A
Other languages
English (en)
French (fr)
Inventor
Toshio Sato
Yoshinosuke Fukuchi
Kenji Toba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Application granted granted Critical
Publication of CA1329541C publication Critical patent/CA1329541C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA000590264A 1988-02-08 1989-02-07 Pharmaceutical composition for relieving side effects of platinum-containing drugs Expired - Fee Related CA1329541C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63-26918 1988-02-08
JP63026918A JPH01203334A (ja) 1988-02-08 1988-02-08 白金を含有する薬剤の副作用軽減剤

Publications (1)

Publication Number Publication Date
CA1329541C true CA1329541C (en) 1994-05-17

Family

ID=12206574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000590264A Expired - Fee Related CA1329541C (en) 1988-02-08 1989-02-07 Pharmaceutical composition for relieving side effects of platinum-containing drugs

Country Status (8)

Country Link
US (1) US4950465A (de)
EP (1) EP0327999B1 (de)
JP (1) JPH01203334A (de)
AT (1) ATE76754T1 (de)
AU (1) AU607584B2 (de)
CA (1) CA1329541C (de)
DE (1) DE68901656T2 (de)
GR (1) GR3005276T3 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122342A1 (en) * 1992-09-04 1994-03-17 Hironori Kawabata Pharmaceutical composition
CN1160123C (zh) * 2003-05-26 2004-08-04 广东天普生化医药股份有限公司 乌司他丁用于治疗严重急性呼吸综合征的用途及其药物组合物
US12702676B2 (en) 2017-05-30 2026-08-11 Meitheal Pharmaceuticals, Inc. Fosfomycin dosing regimens
US11541064B2 (en) * 2017-05-30 2023-01-03 Zavante Therapeutics, Inc. Methods of identifying dosing regimens
JP7778077B2 (ja) 2020-03-05 2025-12-01 ダイアメディカ ユーエスエー インコーポレイテッド ウリナスタチンポリペプチド
US20260191823A1 (en) * 2022-11-21 2026-07-09 Kyowa Hakko Bio Co., Ltd. Prophylactic or therapeutic agent for acute kidney injury induced by anticancer agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028928A (ja) * 1983-07-27 1985-02-14 Meiji Seika Kaisha Ltd 制癌剤の副作用軽減剤
IT1200467B (it) * 1985-05-06 1989-01-18 Boehringer Biochemia Srl Formulazione farmaceutica
JPS62106021A (ja) * 1985-11-01 1987-05-16 Eisai Co Ltd エラスタ−ゼの利用方法

Also Published As

Publication number Publication date
ATE76754T1 (de) 1992-06-15
EP0327999A1 (de) 1989-08-16
AU2955389A (en) 1989-08-10
EP0327999B1 (de) 1992-06-03
GR3005276T3 (de) 1993-05-24
US4950465A (en) 1990-08-21
AU607584B2 (en) 1991-03-07
DE68901656T2 (de) 1993-02-11
JPH01203334A (ja) 1989-08-16
DE68901656D1 (de) 1992-07-09
JPH0560813B2 (de) 1993-09-03

Similar Documents

Publication Publication Date Title
Bonkowsky et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin
US5028627A (en) Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US4485095A (en) Pronase used for the treatment of diseases of the liver and kidneys in humans and animals
EP0689843B1 (de) Lösliches thrombomodulin enthaltende zubereitung
US4762705A (en) Cancer therapy with interferon
US5439939A (en) Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
EP0302754A2 (de) Stabile wässerige Thrombinlösung
KR0137476B1 (ko) 조산아의뇌실내출혈방지용치료제
CA2014470A1 (en) Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
US5393777A (en) Deferration using anguibactin siderophore
EP0327999B1 (de) Pharmazeutische Zusammensetzung zur Milderung der Nebenwirkungen von platinhaltigen Arzneimitteln
EP0124018B1 (de) Pharmazeutische Zubereitung mit Gehalt an gereinigtem Fibrinonectin
US5055295A (en) Lysis of fibrin blood clots with urokinase and pro-urokinase
CA1181006A (en) Therapeutic agent for treating respiratory diseases
US5504065A (en) Agent for treating or preventing AIDS using human urine trypsin inhibitor
Nelson et al. Pharmacology of angiotensin converting enzyme inhibitors: A review
EP0914829B1 (de) Vorbeuge- und/oder heilmittel für das multiple organversagen
KR19990023798A (ko) 항종양제
EP0369035A1 (de) Mittel zur behandlung von pankreatitis oder dergleichen
Lohse et al. Studies on Pancreatic Stones: II. Citrate Secretion in the Canine Pancreatic Juice
US5316775A (en) Method of treating hepatitis B infection
JP2783367B2 (ja) ヘパリン含有製剤
BABKIN Blood sugar concentration and the external secretion of the pancreatic gland
EP0140958B1 (de) Onkolytische arzneimittelkombinationen
WO1993024137A1 (en) Anti-inflammatory agent

Legal Events

Date Code Title Description
MKLA Lapsed